Extranodal diffuse large B‐cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study by Si‐Yuan Chen, Peng‐Peng Xu, Ru Feng, Guo‐Hui Cui, Li Wang, Shu Cheng, Rong‐Ji Mu, Hui‐Lai Zhang, Xiao‐Lei Wei, Yong‐Ping Song, Kai‐Yang Ding, Li‐Hua Dong, Zun‐Min Zhu, Shen‐Miao Yang, Xin Wang, Ting‐Bo Liu, Jian‐Da Hu, Xiao‐Yun Zheng, Ou Bai, Jing‐Yan Xu, Liang Huang, Wei Sang, Ke‐Qian Shi, Fan Zhou, Fei Li, Ai‐Bin Liang, Hui Zhou, Si‐Guo Hao, Hong‐Hui Huang, Bin Xu, Wen‐Bin Qian, Cai‐Xia Li, Zhi‐Ming Li, Chong‐Yang Wu, Xiao‐Bo Wang, Wen‐Yu Shi, Shu‐Ye Wang, Yu‐Yang Tian, Xi Zhang, Ke‐Shu Zhou, Li‐Juan Cui, Hui Liu, Huo Tan, Qing Leng, Dong‐Lu Zhao, Ting Niu, Wei‐Li Zhao

“…Cancer Communications…”
Get full text

Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2‐mediated increase of SOAT2 RNA methylation by Jinhua Jiang, Feng Liu, Dan Cui, Caixia Xu, Jiachang Chi, Tinghua Yan, Fang Guo

“…Cancer Communications…”
Get full text

Combating cancer immunotherapy resistance: a nano‐medicine perspective by Xiangyi Kong, Xintong Xie, Juan Wu, Xiangyu Wang, Wenxiang Zhang, Shuowen Wang, Daria Valerievna Abbasova, Yi Fang, Hongnan Jiang, Jidong Gao, Jing Wang

“…Cancer Communications…”
Get full text

Immunosuppressive JAG2+ tumor‐associated neutrophils hamper PD‐1 blockade response in ovarian cancer by mediating the differentiation of effector regulatory T cells by Chenyang Wang, Moran Yang, Yujing Zhong, Kankan Cao, Xueling Wang, Chen Zhang, Yiying Wang, Mengdi He, Jiaqi Lu, Guodong Zhang, Yan Huang, Haiou Liu

“…Cancer Communications…”
Get full text

Evaluation of exposure‐response‐safety relationship of model‐informed low‐dose 500 mg abiraterone acetate in prostate cancer patients by Edmund Chiong, Ziteng Wang, Eleanor Jing Yi Cheong, Yi Chen Yao, Sin Mun Tham, Revathi Periaswami, Poh Choo Toh, Ziting Wang, Qing Hui Wu, Woon Chau Tsang, Arshvin Kesavan, Alvin Seng Cheong Wong, Patrick Thomas Wong, Felicia Lim, Shuaibing Liu, Eric Chun Yong Chan

“…Cancer Communications…”
Get full text

4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists by Yuji Uehara, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary K. Nesline, Sarabjot Pabla, Jeffrey M. Conroy, Paul DePietro, Heidi Ko, Jason K. Sicklick, Razelle Kurzrock

“…Cancer Communications…”
Get full text

Copper in cancer: friend or foe? Metabolism, dysregulation, and therapeutic opportunities by Dan Shan, Jinling Song, Yuqing Ren, Yuyuan Zhang, Yuhao Ba, Peng Luo, Quan Cheng, Hui Xu, Siyuan Weng, Anning Zuo, Shutong Liu, Xinwei Han, Jinhai Deng, Zaoqu Liu

“…Cancer Communications…”
Get full text

Current status and perspectives of esophageal cancer: a comprehensive review by Wei Jiang, Bo Zhang, Jiaqi Xu, Liyan Xue, Luhua Wang

“…Cancer Communications…”
Get full text

Reflections and insights into the evolution of restrictive eligibility criteria for cancer clinical trials in China and beyond by Huiyao Huang, Huilei Miao, Jinling Tang, Ning Li

“…Cancer Communications…”
Get full text

Expression profiling of primary and metastatic oral squamous cell carcinoma identifies progression‐associated transcriptome changes and therapeutic vulnerabilities by Jonas Pyko, Markus Glaß, Julia Rosemann, Matthias Kappler, Jana Macho, Sarah Qasem, Stefan Hüttelmaier, Alexander W. Eckert, Monika Haemmerle, Tony Gutschner

“…Cancer Communications…”
Get full text

Discovery of a novel viroid‐like circular RNA in colorectal cancer by Meini Wu, Wenliang Li, Ningzhu Hu, Changning Liu, Jianfang Li, Yanhan Li, Ning Xu, Jiandong Shi, Jing Sun, Jing Li, Yunzhang Hu

“…Cancer Communications…”
Get full text

Exciting progress in targeted therapy innovation for unresectable stage III EGFR‐mutated NSCLC: the phase III LAURA study by Ziyan Tong, Ning Zhu, Hong Shen, Ying Yuan

“…Cancer Communications…”
Get full text

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III tri... by Shun Lu, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, Junguo Lu, Shaoshui Chen, Dongqing Lv, Guojun Zhang, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui, Xingxiang Xu, Jian Fang, Jifeng Feng, Zhi Xu, Rui Ma, Jie Hu, Nong Yang, Xiangdong Zhou, Xiaohong Wu, Chengping Hu, Zhihong Zhang, You Lu, Yanping Hu, Liyan Jiang, Qiming wang, Renhua Guo, Jianying Zhou, Baolan Li, Chunhong Hu, Wancheng Tong, Helong Zhang, Lin Ma, Yuan Chen, Zhijun Jie, Yu Yao, Longzhen Zhang, Jie Weng, Weidong Li, Jianping Xiong, Xianwei Ye, Jianchun Duan, Haihua Yang, Meili Sun, Hongying Wei, Jiawei Wei, Zheyu Zhang, Qiong Wu

“…Cancer Communications…”
Get full text

First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial by Ying Cheng, Shuang Zhang, Liang Han, Lin Wu, Jun Chen, Peiyan Zhao, Hongmei Sun, Guilan Wen, Yinghua Ji, Anastasia Zimina, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Tamar Melkadze, Yueyin Pan, Xuhong Min, Maksym Viguro, Xingya Li, Yanqiu Zhao, Junquan Yang, Tamta Makharadze, Ekaterine Arkania, Haoyu Yu, Jing Li, Fang Yang, Xinyi Yang, Chen Ling, Qingyu Wang, Yongqiang Shan, Jun Zhu, the ASTRUM‐005 Study Group

“…Cancer Communications…”
Get full text

Whole‐genome CRISPR‐Cas9 knockout screens identify SHOC2 as a genetic dependency in NRAS‐mutant melanoma by Andrea Y. Gu, Tet Woo Lee, Aziza Khan, Xuenan Zhang, Francis W. Hunter, Dean C. Singleton, Stephen M. F. Jamieson

“…Cancer Communications…”
Get full text

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2‐ breast cancer‐FINEST study by Li Chen, Wen‐Ya Wu, Fei Liang, Guang‐Yu Liu, Ke‐Da Yu, Jiong Wu, Gen‐Hong Di, Lei Fan, Zhong‐Hua Wang, Jun‐Jie Li, Zhi‐Ming Shao

“…Cancer Communications…”
Get full text

Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy by Mengyi Lao, Xiaozhen Zhang, Zejun Li, Kang Sun, Hanshen Yang, Sicheng Wang, Lihong He, Yan Chen, Hanjia Zhang, Jiatao Shi, Daqian Xu, Tingbo Liang, Xueli Bai

“…Cancer Communications…”
Get full text

Genomic imprinting biomarkers for cervical cancer risk stratification by Xue Xiao, Wei Wang, Peng Bai, Ying Chen, Zhengwen Qin, Tong Cheng, Xing Li, John P. Pineda, Panying Shi, Xiaonan Wang, Jianhong Wang, Lian Xu, Xuemei Gao, Huixian Zheng, Lulu Yang, Wenyi Lin, Wenbin Huang, Rulong Shen, Changjun Yue, Huixiong Xu, Felipe Batalini, Yang Liu, Ning Zhou, Yaoyao Zhang, Hanmin Liu

“…Cancer Communications…”
Get full text

Deciphering the transcriptomic landscape of early HR+/HER2− breast cancer in very young women by Iris Garrido‐Cano, Marta Tapia, Juan Carbonell, Carlos Peña, Sandra Torres‐Ruiz, Anna Ágreda‐Roca, Ana Lameirinhas, Cristina Tebar, Octavio Burgués, Cristina Hernando, Ana Lluch, Fara Brasó‐Maristany, Aleix Prat, Begoña Bermejo, María Teresa Martínez, Juan Miguel Cejalvo

“…Cancer Communications…”
Get full text

Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross‐over pharmacokinetic drug‐drug interaction study by Niels Heersche, Daan A. C. Lanser, Esther Oomen‐de Hoop, Attila Içli, Peter deBruijn, Marthe S. Paats, Elisabeth F. C. vanRossum, Stijn L. W. Koolen, Ron H. N. vanSchaik, Anne‐Marie C. Dingemans, G. D. Marijn Veerman, Ron H. J. Mathijssen

“…Cancer Communications…”
Get full text